Effect of directly acting antivirals for hepatitis C virus infection on proprotein convertase subtilisin/kexin type 9 level.
PCSK9
cardiovascular diseases
chronic
hepatitis C
risk
Journal
Health science reports
ISSN: 2398-8835
Titre abrégé: Health Sci Rep
Pays: United States
ID NLM: 101728855
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
10
08
2020
revised:
02
03
2021
accepted:
16
03
2021
entrez:
10
5
2021
pubmed:
11
5
2021
medline:
11
5
2021
Statut:
epublish
Résumé
Eradication of the hepatitis C virus (HCV) may affect proprotein convertase subtilisin/kexin type 9 (PCSK9) levels and cardiovascular risk. However, information regarding PCSK9 level after HCV eradication is lacking. Hence, in this case-control retrospective study, we aimed to evaluate PCSK9 level from pretherapy baseline up to sustained virological response (SVR). Eighty-four patients treated with directly acting antivirals (DAAs) between July 2015 and May 2018 were enrolled. Differences in baseline PCSK9 level due to absence/presence of recorded baseline characteristics (covariates) were evaluated. Changes in PCSK9 levels from pretherapy to SVR (ΔPCSK9) and their correlations with the covariates were assessed. The repeated measures analysis of variance was used to investigate the differences in PCSK9 level from the baseline to the achievement of SVR due to absence/presence of any covariate. The mean age of the patients was 67.6 ± 11 years, and 53.6% were males. Baseline PCSK9 levels were statistically lower in patients using statins than in those not using statins (mean, 70.3 ± 43.1 ng/mL vs 271.8 ± 252.2 ng/mL; The reduction in mean PCSK9 level from baseline pretherapy to after HCV eradication was statistically significant. Whether PCSK9 is a new biomarker for cardiovascular risk in these patients remains to be ascertained.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Eradication of the hepatitis C virus (HCV) may affect proprotein convertase subtilisin/kexin type 9 (PCSK9) levels and cardiovascular risk. However, information regarding PCSK9 level after HCV eradication is lacking. Hence, in this case-control retrospective study, we aimed to evaluate PCSK9 level from pretherapy baseline up to sustained virological response (SVR).
METHODS
METHODS
Eighty-four patients treated with directly acting antivirals (DAAs) between July 2015 and May 2018 were enrolled. Differences in baseline PCSK9 level due to absence/presence of recorded baseline characteristics (covariates) were evaluated. Changes in PCSK9 levels from pretherapy to SVR (ΔPCSK9) and their correlations with the covariates were assessed. The repeated measures analysis of variance was used to investigate the differences in PCSK9 level from the baseline to the achievement of SVR due to absence/presence of any covariate.
RESULTS
RESULTS
The mean age of the patients was 67.6 ± 11 years, and 53.6% were males. Baseline PCSK9 levels were statistically lower in patients using statins than in those not using statins (mean, 70.3 ± 43.1 ng/mL vs 271.8 ± 252.2 ng/mL;
CONCLUSIONS
CONCLUSIONS
The reduction in mean PCSK9 level from baseline pretherapy to after HCV eradication was statistically significant. Whether PCSK9 is a new biomarker for cardiovascular risk in these patients remains to be ascertained.
Identifiants
pubmed: 33969232
doi: 10.1002/hsr2.273
pii: HSR2273
pmc: PMC8088586
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e273Informations de copyright
© 2021 The Authors. Health Science Reports published by Wiley Periodicals LLC.
Déclaration de conflit d'intérêts
Nothing to declare.
Références
Ann Hepatol. 2017 Dec 27;17(1):64-75
pubmed: 29311405
Vascul Pharmacol. 2014 Aug;62(2):94-102
pubmed: 24685817
Hepatology. 2005 Jan;41(1):48-54
pubmed: 15690481
J Clin Med. 2020 Sep 28;9(10):
pubmed: 32998342
J Am Heart Assoc. 2016 Apr 29;5(5):
pubmed: 27130349
J Clin Invest. 2006 Nov;116(11):2995-3005
pubmed: 17080197
J Cell Physiol. 2017 Sep;232(9):2330-2338
pubmed: 28063230
Curr Opin Lipidol. 2014 Oct;25(5):387-93
pubmed: 25110901
EBioMedicine. 2017 Sep;23:68-78
pubmed: 28864162
Pharmacol Ther. 2018 Mar;183:118-126
pubmed: 29024739
BMC Infect Dis. 2018 Oct 16;18(1):518
pubmed: 30326844
Glob Cardiol Sci Pract. 2017 Mar 31;2017(1):e201702
pubmed: 28971102
Atherosclerosis. 2020 Mar;296:40-47
pubmed: 32005004
J Hepatol. 2018 Aug;69(2):461-511
pubmed: 29650333
J Virol. 2014 Mar;88(5):2519-29
pubmed: 24352472
J Antimicrob Chemother. 2011 Aug;66(8):1861-8
pubmed: 21622971
Hosp Pract (1995). 2019 Aug;47(3):105-110
pubmed: 31018721
J Lipid Res. 2012 Dec;53(12):2515-24
pubmed: 22811413
Hepatology. 2007 Jul;46(1):32-6
pubmed: 17567829
Drug Discov Today. 2017 Jun;22(6):883-895
pubmed: 28111330
Dig Liver Dis. 2017 Oct;49(10):1133-1138
pubmed: 28572039
BMC Infect Dis. 2012;12 Suppl 2:S9
pubmed: 23173812
Medicine (Baltimore). 2015 Dec;94(52):e2426
pubmed: 26717403
Medicina (Kaunas). 2020 Feb 28;56(3):
pubmed: 32121135
Drug Saf. 2018 Jan;41(1):77-86
pubmed: 28786035
Biomed Rep. 2019 Mar;10(3):156-164
pubmed: 30906544
Clin Mol Hepatol. 2019 Mar;25(1):30-36
pubmed: 30669818
Med J Aust. 1964 Aug 22;2:320-1
pubmed: 14194486
Gastroenterology. 2019 Mar;156(4):987-996.e8
pubmed: 30445009